- Home
- DMAC vs EB Comparison
DMAC vs EB Comparison
Compare DMAC & EB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- EB
- Stock Information
- Founded
- DMAC 2000
- EB 2003
- Country
- DMAC United States
- EB United States
- Employees
- DMAC N/A
- EB N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- EB EDP Services
- Sector
- DMAC Health Care
- EB Technology
- Exchange
- DMAC Nasdaq
- EB Nasdaq
- Market Cap
- DMAC 310.1M
- EB 261.5M
- IPO Year
- DMAC N/A
- EB 2018
- Fundamental
- Price
- DMAC $6.87
- EB $2.91
- Analyst Decision
- DMAC Strong Buy
- EB Buy
- Analyst Count
- DMAC 3
- EB 2
- Target Price
- DMAC $12.33
- EB $5.25
- AVG Volume (30 Days)
- DMAC 448.5K
- EB 452.1K
- Earning Date
- DMAC 11-12-2025
- EB 11-06-2025
- Dividend Yield
- DMAC N/A
- EB N/A
- EPS Growth
- DMAC N/A
- EB N/A
- EPS
- DMAC N/A
- EB N/A
- Revenue
- DMAC N/A
- EB $300,856,000.00
- Revenue This Year
- DMAC N/A
- EB N/A
- Revenue Next Year
- DMAC N/A
- EB $9.53
- P/E Ratio
- DMAC N/A
- EB N/A
- Revenue Growth
- DMAC N/A
- EB N/A
- 52 Week Low
- DMAC $3.19
- EB $1.81
- 52 Week High
- DMAC $7.49
- EB $4.12
- Technical
- Relative Strength Index (RSI)
- DMAC 63.84
- EB 65.10
- Support Level
- DMAC $6.83
- EB $2.69
- Resistance Level
- DMAC $7.41
- EB $2.78
- Average True Range (ATR)
- DMAC 0.43
- EB 0.09
- MACD
- DMAC 0.03
- EB 0.01
- Stochastic Oscillator
- DMAC 73.62
- EB 90.28
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About EB Eventbrite Inc.
Eventbrite Inc is a self-service ticketing and experience technology platform that serves event creators. The company's two-sided marketplace connects creators and consumers every month to share their passions, artistry, and causes through live experiences. Creators use its self-service ticketing and marketing tools to plan, promote, and sell tickets to their events, and event seekers use its website and mobile application to discover and purchase tickets to experiences. Geographically, it generates maximum revenue from the United States. The company generates revenues principally from service fees and payment processing fees from the sale of paid tickets on its platform.